{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:03Z","timestamp":1791176883891,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2334-14-351","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T07:22:28Z","timestamp":1403767348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program"],"prefix":"10.1186","volume":"14","author":[{"given":"Amber L","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Kvizhinadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"issue":"5","key":"3648_CR1","doi-asserted-by":"publisher","first-page":"f157","DOI":"10.1016\/j.vaccine.2012.06.091","volume":"30S","author":"K Canfell","year":"2012","unstructured":"Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ: Modeling preventative strategies against Human Papillomavirus-related disease in developed countries. Vaccine. 2012, 30S (5): f157-f167.","journal-title":"Vaccine"},{"issue":"3","key":"3648_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jnci\/djs491","volume":"105","author":"A Jemal","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya O, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Chymura MJ, Anderson RN, Yankey BK Edwards D: Annual report of the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013, 105 (3): 175-201.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3648_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/sj.bjc.6606091","volume":"104","author":"J Hocking","year":"2011","unstructured":"Hocking J, Stein A, Conway E, Regan DG, Grulick A, Law M, Brotherton J: Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer. 2011, 104 (5): 886-891.","journal-title":"Br J Cancer"},{"issue":"1","key":"3648_CR4","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.vaccine.2011.01.015","volume":"29","author":"F Jin","year":"2011","unstructured":"Jin F, Stein A, Conway E, Regan DG, Law M, Brotherton J, Hocking J, Grulich AE: Trends in anal cancer in Australia, 1982\u20132005. Vaccine. 2011, 29 (1): 2322-2327.","journal-title":"Vaccine"},{"key":"3648_CR5","volume-title":"Cancer Epidemiol","author":"JM Elwood","year":"2014","unstructured":"Elwood JM, Youlden DR, Chelimo C, Ioannides SJ, Baade PD: Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiol. 2014, in press"},{"key":"3648_CR6","doi-asserted-by":"publisher","first-page":"f2032","DOI":"10.1136\/bmj.f2032","volume":"346","author":"A Hammad","year":"2013","unstructured":"Hammad A, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into naitonal human papillomavirus vaccination programme: national surveillance data. BMJ. 2013, 346: f2032-","journal-title":"BMJ"},{"issue":"6","key":"3648_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/infdis\/jis405","volume":"206","author":"A Leval","year":"2012","unstructured":"Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, Simard JF: Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012, 206 (6): 860-866.","journal-title":"J Infect Dis"},{"issue":"1339","key":"3648_CR8","first-page":"51","volume":"124","author":"J Oliphant","year":"2011","unstructured":"Oliphant J, Perkins N: Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J. 2011, 124 (1339): 51-58.","journal-title":"N Z Med J"},{"key":"3648_CR9","volume-title":"Sexually transmitted infectious diseases in New Zealand 2011","author":"ESR","year":"2012","unstructured":"ESR: Sexually transmitted infectious diseases in New Zealand 2011. 2012, Porirua: ESR, \n                    http:\/\/www.surv.esr.cri.nz\/PDF_surveillance\/STISurvRpt\/2011\/2011AnnualSTIRpt.pdf\n                    \n                   2012"},{"issue":"50","key":"3648_CR10","first-page":"1705","volume":"60","author":"MMWR","year":"2011","unstructured":"MMWR: Recommendations of the use of quadrivalent human papillomavirus vaccine in laes - Advisory committee on immunization practices (ACIP), 2011. Morb Mortal Wkly Rep. 2011, 60 (50): 1705-1708.","journal-title":"Morb Mortal Wkly Rep"},{"key":"3648_CR11","volume-title":"Immunise Australia Program. The National HPV Vaccination Program Register","author":"Australian Government Department of Health and Ageing","year":"2011","unstructured":"Australian Government Department of Health and Ageing: Immunise Australia Program. The National HPV Vaccination Program Register. 2011, \n                    http:\/\/www.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/immunise-hpv\n                    \n                  . 2011"},{"issue":"7","key":"3648_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.5694\/mja12.10025","volume":"196","author":"PD Massey","year":"2012","unstructured":"Massey PD, Durrheim DN: Universal human papillomavirus vaccination of Australian boys - neither cost-effective nor equitable. Med J Aust. 2012, 196 (7): 446-","journal-title":"Med J Aust"},{"key":"3648_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/infdis\/jir285","volume":"204","author":"M Brisson","year":"2011","unstructured":"Brisson M, van de Velde N, Franco E, Drolet M, Boily M: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011, 204: 372-376.","journal-title":"J Infect Dis"},{"issue":"3","key":"3648_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","volume":"96","author":"K French","year":"2007","unstructured":"French K, Barnabas R, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett G: Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex- specific pattern of vaccination in Finland. Br J Cancer. 2007, 96 (3): 514-518.","journal-title":"Br J Cancer"},{"issue":"48","key":"3648_CR15","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","volume":"29","author":"M Smith","year":"2011","unstructured":"Smith M, Lew J, Walker R, Brotherton J, Nickson C, Canfell K: The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011, 29 (48): 9112-9122.","journal-title":"Vaccine"},{"key":"3648_CR16","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","volume":"29","author":"HW Chesson","year":"2011","unstructured":"Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE: The cost-effectivenss of male HPV vaccination in the United States. Vaccine. 2011, 29: 8443-8450.","journal-title":"Vaccine"},{"issue":"12","key":"3648_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","volume":"10","author":"JJ Kim","year":"2010","unstructured":"Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010, 10 (12): 845-852.","journal-title":"Lancet Infect Dis"},{"issue":"37","key":"3648_CR18","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1016\/j.vaccine.2012.06.057","volume":"30","author":"T Cummings","year":"2012","unstructured":"Cummings T, Zimet G, Brown D, Tu W, Yang Z, Fortenberry J, Shew M: Reuction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012, 30 (37): 5496-5499.","journal-title":"Vaccine"},{"key":"3648_CR19","volume-title":"Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report NoXXX. Wellington","author":"T Blakely","year":"2012","unstructured":"Blakely T, Foster R, Wilson N: BODE3 Team: Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Study Protocol. Version 2.0. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report NoXXX. Wellington. 2012, Wellington: Department of Public Health, University of Otago"},{"key":"3648_CR20","volume-title":"Vaccine","author":"T Blakely","year":"2014","unstructured":"Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N: Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014, [Epublication date 21 March 2014]: doi:10.1016\/j.vaccine.2014.02.071"},{"key":"3648_CR21","unstructured":"Prices and purchasing power parities (PPP). [\n                    http:\/\/www.oecd.org\/std\/prices-ppp\/\n                    \n                  ]"},{"key":"3648_CR22","volume-title":"Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3) Technical Report: Number 4","author":"G Kvizhinadze","year":"2011","unstructured":"Kvizhinadze G, Blakely T: Projected New Zealand Lifetables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3) Technical Report: Number 4. 2011, Wellington: Department of Public Health, University of Otago"},{"key":"3648_CR23","volume-title":"Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No10","author":"T Blakely","year":"2012","unstructured":"Blakely T, Costilla R, Soeberg M: Cancer excess mortality rates over 2006\u20132026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No10. 2012, Wellington: Department of Public Health, University of Otago, Wellington"},{"key":"3648_CR24","volume-title":"Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No5","author":"R Costilla","year":"2011","unstructured":"Costilla R, Atkinson J, Blakely T: Incorporating Ethnic and Deprivation Variation to Cancer Incidence Estimates over 2006\u20132026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No5. 2011, Wellington: Department of Public Health, University of Otago, Wellington"},{"key":"3648_CR25","volume-title":"New Zealand Cancer Registry","author":"Ministry of Health","year":"2013","unstructured":"Ministry of Health: New Zealand Cancer Registry. 2013, Wellington: Ministry of Health"},{"key":"3648_CR26","volume-title":"National Cervical Screening Programme Monitoring Report Number 34: 1 July \u2013 31 December 2010","author":"M Smith","year":"2012","unstructured":"Smith M, Walker R, Canfell K: National Cervical Screening Programme Monitoring Report Number 34: 1 July \u2013 31 December 2010. 2012, Wellington: National Screening Unit, Ministry of Health"},{"issue":"9859","key":"3648_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, et al: Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012, 380 (9859): 2129-2143.","journal-title":"Lancet"},{"key":"3648_CR28","volume-title":"HPV immunisation programme","author":"Ministry of Health","year":"2013","unstructured":"Ministry of Health: HPV immunisation programme. 2013, Wellington: Ministry of Health"},{"issue":"2","key":"3648_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jadohealth.2009.11.199","volume":"46","author":"N Liddon","year":"2010","unstructured":"Liddon N, Hood J, Wynn BA, Markowitz LE: Acceptibility of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010, 46 (2): 113-123.","journal-title":"J Adolesc Health"},{"issue":"10","key":"3648_CR30","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1097\/chi.0b013e3180f6340e","volume":"46","author":"S Ramrakha","year":"2007","unstructured":"Ramrakha S, Bell M, Paul C, Dickson N, Moffitt T, Caspi A: Childhood Behavior Problems Linked to Sexual Risk Taking in Young Adulthood: A Birth Cohort Study. J Am Acad Child Adolesc Psychiatry. 2007, 46 (10): 1272-1279.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"3648_CR31","first-page":"59","volume":"15","author":"W Boyce","year":"2006","unstructured":"Boyce W: Sexual Health of Canadian Youth: Findings from the Canadian Youth Sexual Health and HIV\/AIDS Study. Can J Hum Sex. 2006, 15 (2): 59-","journal-title":"Can J Hum Sex"},{"issue":"85","key":"3648_CR32","first-page":"111","volume":"4","author":"F Marra","year":"2009","unstructured":"Marra F, Ogilvie G, Colley L, Kiliewer E, Marra C: Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009, 4 (85): 111-115.","journal-title":"Sex Transm Infect"},{"key":"3648_CR33","volume-title":"Sexually Transmitted Infections in New Zealand: Annual Surveillance Repor","author":"The Institute of Environmental Science and Research Ltd","year":"2011","unstructured":"The Institute of Environmental Science and Research Ltd: Sexually Transmitted Infections in New Zealand: Annual Surveillance Repor. 2011, Porirua, New Zealand: ESR"},{"key":"3648_CR34","volume-title":"vol. Table: Threshold values for intervention costeffectiveness by region","author":"WHO","year":"2012","unstructured":"WHO: Choosing interventions that are cost effective (WHOCHOICE). vol. Table: Threshold values for intervention costeffectiveness by region. 2012, Geneva: World Health Organization"},{"issue":"46","key":"3648_CR35","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","volume":"29","author":"H Chesson","year":"2011","unstructured":"Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L: The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011, 29 (46): 8443-8450.","journal-title":"Vaccine"},{"issue":"42","key":"3648_CR36","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","volume":"28","author":"E Elbasha","year":"2010","unstructured":"Elbasha E, Dasbach E: Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010, 28 (42): 6858-6867.","journal-title":"Vaccine"},{"key":"3648_CR37","doi-asserted-by":"publisher","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"J Kim","year":"2009","unstructured":"Kim J, Goldie S: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009, 339: b3884-","journal-title":"BMJ"},{"key":"3648_CR38","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.vaccine.2013.01.026","volume":"31","author":"T Malagon","year":"2013","unstructured":"Malagon T, Joumier V, Boily M, Van de Velde N, Drolet M, Brisson M: The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine. 2013, 31: 1740-1747.","journal-title":"Vaccine"},{"key":"3648_CR39","volume-title":"HPV Immunisation Programme Implementaiton Evaluation: File Report","author":"Litmus","year":"2012","unstructured":"Litmus: HPV Immunisation Programme Implementaiton Evaluation: File Report. 2012, Wellington: Prepared for the New Zealand Ministry of Health, vol. 1","edition":"vol. 1"},{"issue":"6","key":"3648_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jadohealth.2013.09.018","volume":"53","author":"S Hariri","year":"2013","unstructured":"Hariri S, Markowitz LE, Dunne EF, Unger ER: Population Impact of HPV Vaccines: Summary of Early Evidence. J Adolesc Health. 2013, 53 (6): 679-682.","journal-title":"J Adolesc Health"},{"issue":"10","key":"3648_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malag\u00f3n","year":"2012","unstructured":"Malag\u00f3n T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, Brisson M: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12 (10): 781-789.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-14-351\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T10:25:07Z","timestamp":1548239107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-14-351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-14-351","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]},"assertion":[{"value":"5 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"351"}}